Europese Unie - Tsjechisch - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastická činidla - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. další informace o stavu receptoru lidského epidermálního růstového faktoru 2 (her2) naleznete v části 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. další informace o stavu her2 naleznete v části 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

bayer ag, leverkusen array - 5562 moxifloxacin-hydrochlorid - potahovaná tableta - 400mg - moxifloxacin

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

aurovitas, spol. s r.o., praha array - 5562 moxifloxacin-hydrochlorid - potahovaná tableta - 400mg - moxifloxacin

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

olikla s.r.o., kostelec nad Černými lesy array - 5562 moxifloxacin-hydrochlorid - potahovaná tableta - 400mg - moxifloxacin

Europese Unie - Tsjechisch - EMA (European Medicines Agency)

mylan ire healthcare limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastická činidla - treatment of carcinoma of the colon or rectum, breast cancer, non-small cell lung cancer, renal cell cancer, epithelial ovarian, fallopian tube or primary peritoneal cancer, and carcinoma of the cervix.

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

vivanta generics s.r.o., praha array - 5562 moxifloxacin-hydrochlorid - potahovaná tableta - 400mg - moxifloxacin

Europese Unie - Tsjechisch - EMA (European Medicines Agency)

sanofi winthrop industrie - aflibercept - kolorektální novotvary - antineoplastická činidla - léčba metastatického kolorektálního karcinomu (mcrc).

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

opella healthcare czech s.r.o., praha array - 1064 paracetamol; 1122 fenylefrin-hydrochlorid - granule pro perorální suspenzi - 650mg/10mg - paracetamol, kombinace kromĚ psycholeptik

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

sandoz gmbh, kundl array - 2544 benzathin-fenoxymethylpenicilin - perorální suspenze - 0,4miu/5ml - benzathin-fenoxymethylpenicilin

Tsjechië - Tsjechisch - SUKL (Státní ústav pro kontrolu léčiv)

sandoz gmbh, kundl array - 2544 benzathin-fenoxymethylpenicilin - perorální suspenze - 0,75miu/5ml - benzathin-fenoxymethylpenicilin